


For Immediate Release:
April 28, 2016

Media Contact:
Katie Kiley Brown, NCCN
215.690.0238
brown@nccn.org

New NCCN Resources for Non-Hodgkin's Lymphomas Empower Patients to Make Informed Treatment Decisions

NCCN has published new patient education materials for Diffuse Large B-Cell, Follicular, Mantle Cell, and Peripheral T-Cell Lymphomas; these resources are available for download free of charge at NCCN.org/patients and print versions may be ordered through Amazon.com.



FORT WASHINGTON, PA —It is estimated that more than 72,000 people in the United States will be diagnosed with Non-Hodgkin's Lymphomas (NHL) in 2016¹. The sixth leading cancer diagnosis in U.S. men and women², NHL has more than 30

sub-types, each featuring unique treatment choices and challenges.³

To further educate people with NHL and empower them to make informed treatment decisions for their disease, the [National Comprehensive Cancer Network®](http://NationalComprehensiveCancerNetwork.org) (NCCN®), through support of the [NCCN Foundation®](http://NCCNFoundation.org), has published [NCCN Guidelines for Patients®](http://NCCNGuidelines.org) and [NCCN Quick Guide™](http://NCCNQuickGuide.org) series for NHL, specifically for Diffuse Large B-Cell, Follicular, Mantle Cell, and Peripheral T-Cell Lymphomas. The NCCN Guidelines for Patients®: Diffuse Large B-Cell Lymphoma and Follicular Lymphoma are made possible, in part, through generous sponsorship from The Leukemia & Lymphoma Society.

These patient reference booklets are part of a larger series of patient education materials for NHL that also includes Chronic Lymphocytic Leukemia, which was published earlier this year. NCCN Guidelines for Patients® for Mycosis Fungoides is also expected to publish soon.

¹ "Cancer Facts & Figures 2016." American Cancer Society. Web. 28 Apr. 2016.

² "Cancer Facts & Figures 2016." American Cancer Society. Web. 28 Apr. 2016.

³ "Non-Hodgkin Lymphoma." The Leukemia & Lymphoma Society. 27 Apr. 2016.

New NCCN Resources for Non-Hodgkin's Lymphomas Empower Patients to Make Informed Treatment Decisions

“The goal of the NCCN Foundation is to deliver true insight to people living with the challenges and complexities of a cancer diagnosis so they can take an active role in their care and the care of their loved ones,” said Marcie R. Reeder, MPH, Executive Director, NCCN Foundation. “We are proud to collaborate with The Leukemia & Lymphoma Society to make these resources available for people with Non-Hodgkin's Lymphomas.”

NCCN Guidelines for Patients, translations of the [NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\)](#), are designed to provide people with cancer and their caregivers with state-of-the-art treatment information in easy-to-understand language. The NCCN Guidelines® are developed by multidisciplinary, volunteer panels of experts from the NCCN Member Institutions and feature algorithms that address appropriate management options from initial work-up through the course of the disease.

NCCN Guidelines for Patients and the NCCN Quick Guide™ series, abbreviated references outlining key points of the NCCN Guidelines for Patients, are written according to plain language principles to improve health literacy with clean design and formats featuring patient-friendly elements, such as medical illustrations of anatomy, tests, and treatments. These resources also feature an expansive glossary of terms and acronyms. The NCCN Guidelines for Patients and the NCCN Quick Guide™ series do not replace the expertise and clinical judgment of the physician.

NCCN currently offers NCCN Guidelines for Patients for the following: Breast, Colon, Esophageal, Kidney, Non-Small Cell Lung, Ovarian, Pancreatic, and Prostate Cancers; Acute Lymphoblastic Leukemia (ALL); Caring for Adolescents and Young Adults (AYA); Chronic Myelogenous Leukemia (CML); Hodgkin Lymphoma, Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; NHL; and Soft Tissue Sarcoma.

To download for free or order the NCCN Guidelines for Patients and NCCN Quick Guide™ series for NHL, visit [NCCN.org/patients](https://www.nccn.org/patients).

###

About NCCN Foundation

Through philanthropy, the NCCN Foundation® empowers people through knowledge and advances the mission of NCCN to improve the quality, effectiveness, and efficiency of cancer care, so that patients can live better lives. Visit [NCCNFoundation.org](https://www.nccnfoundation.org).

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to

New NCCN Resources for Non-Hodgkin's Lymphomas Empower Patients to Make Informed Treatment Decisions

improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit [NCCN.org](https://www.nccn.org). Patients and caregivers, visit [NCCN.org/patients](https://www.nccn.org/patients). Media, visit [NCCN.org/news](https://www.nccn.org/news).